Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Celularity Inc. is a biotechnology company focused on developing allogeneic cell therapies derived from placental cells. The company operates primarily in the United States and is working on innovative treatments for cancer and degenerative diseases, leveraging its unique platform for cell-based therapies.
Celularity generates revenue through the development and commercialization of its proprietary cell therapies, which are designed to treat various conditions. Its competitive advantage lies in its unique access to placental-derived cells, which are abundant and have immunomodulatory properties, potentially leading to better patient outcomes.
Clinical trial results for lead therapies, particularly in oncology
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from the FDA for new treatments
Market adoption rates of cell therapies in targeted indications
Regulatory changes affecting biotechnology approvals
Technological disruption from competing therapies
Emergence of new cell therapy competitors
Potential for larger pharmaceutical companies to dominate the market
High operating losses leading to liquidity concerns
Dependence on external funding for R&D
low - The demand for biotechnology products is less sensitive to economic cycles, as healthcare spending tends to remain stable.
Moderate - Rising interest rates could increase the cost of capital for funding R&D and operational expansion, impacting growth potential.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on credit for operations.
growth - Investors looking for high-risk, high-reward opportunities in innovative biotechnologies.
high - The stock has exhibited significant volatility, reflected in its -87.4% return over the past year.
